摘要
目的:研究术前支气管动脉灌注(bronchial artery infusion,BAI)化疗对局部晚期(Ⅲ期)非小细胞肺癌(NSCLC)围手术期的影响,评价其安全性及可行性。方法:92例局部晚期NSCLC患者随机分为两组:BAI处理组,先给予2个疗程的BAI化疗后进行手术治疗;单纯手术组,确诊后直接手术。比较两组患者的手术完全性切除率及围手术期并发症。结果:BAI处理组的临床有效率为68.3%,毒副反应轻。BAI处理组的手术完全性切除率(90.2%)高于单纯手术组(77.1%),但未达到统计学差异(P>0.05)。两组患者术中失血量、手术并发症和手术死亡率比较均无明显差异。结论:术前BAI化疗安全有效,可获得较好的手术完全切除率和临床疗效,并不增加围手术期并发症和死亡率。
Objective：To evaluate preoperative bronchial artery infusion chemotherapy on operation in patients with locally advanced （ stage Ⅲ ） non-small cell lung cancer（ NSCLC ）. Methods ： Ninty-two cases with locally advanced NSCLC patients were randomly divided into two groups. BAI chemotherapy group was received BAI chemotherapy for 2 courses and followed surgery ; Surgery alone group was treated by operation alone. The complete resection rate and perioperative complications were compared between the two groups. Results：In BAI chemotherapy group, the rate of clinical response was 68.3% , slight toxicity was observed. In BAI chemotherapy group surgery complete resection rate was 90. 2% , which was significantly higher than surgery alone group （77. 1% ） （P 〉0. 05 ）. There weren＇t significant differences of blood loss, operative complications and mortality between the two groups. Conclusion： BAI neoadjuvant chemotherapy is safe and effective, which has a better clinical response. It can increase the complete resection rate of the tumor and not increase the operative complications and mortality.
出处
《临床肿瘤学杂志》
CAS
2008年第1期26-28,共3页
Chinese Clinical Oncology
基金
大连市科学技术基金资助项目(20039907)
